Brief: Sol-Gel Technologies And Galderma Announce FDA Approval Of Epsolay
25/04/2022 12:10
April 25 (Reuters) - Sol Gel Technologies Ltd SLGL.O :
* SOL-GEL TECHNOLOGIES AND GALDERMA ANNOUNCE FDA APPROVAL OF EPSOLAY
* SOL GEL TECHNOLOGIES LTD - GRANTED TO GALDERMA HOLDING SA, EXCLUSIVE
RIGHTS TO
COMMERCIALIZE EPSOLAY IN UNITED STATES
Source text for Eikon: ID:nGNX3fMgK9
Further company coverage: SLGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SOL-GEL TECHNOLOGIES
See all newsIsraeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale
SOL-GEL TECHNOLOGIES LTD. expected to post a loss of $2.57 a share - Earnings Preview
Sol-Gel Q1 revenue falls sharply on milestone payment impact
Brief: Sol-Gel Technologies Ltd. Q1 Revenue USD 100 Thousand
Brief: Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering